EUVIMEDEUVIMED entdecken
Crossref

Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease

Davis Cammann iD, Jeffrey L Cummings iD, Yadi Zhou iD, Feixiong Cheng iD, Jingchun Chen iD

Journal of Alzheimer’s Disease · 18.11.2026

DOI: 10.1177/13872877261507113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 18.11.2026. Verfasst von Davis Cammann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Mountain West Clinical and Translational Research Infrastructure Network Program, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies.

Objective

We sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways.

Methods

We identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than −2.0, a false-discovery rate corrected p -value less than 0.05, and evidence in transgenic mouse models or AD clinical trials.

Results

We found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models.

Conclusions

We provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseasedrug repurposingimmune systeminflammationnetwork medicineprotein interactions

Autor:innen und Institutionen

  • Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA.
  • Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA.
  • Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

ORCID-Profile: Davis Cammann, Jeffrey L Cummings, Yadi Zhou, Feixiong Cheng, Jingchun Chen

Förderung

  • Mountain West Clinical and Translational Research Infrastructure Network Program
  • National Institute of General Medical Sciences
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Cammann, D., Cummings, J. L., Zhou, Y., Cheng, F., & Chen, J. (2026). Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507113

Vancouver

Cammann D, Cummings JL, Zhou Y, Cheng F, Chen J. Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507113

BibTeX
@article{Cammann2026,
  author = {Cammann, Davis and Cummings, Jeffrey L and Zhou, Yadi and Cheng, Feixiong and Chen, Jingchun},
  title = {Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  doi = {10.1177/13872877261507113}
}
Kostenlos starten →